Notably, although we tested the biohybrid‐engineered bacteria in three tumor models with high CDH17 expression, and examined their anti‐tumor performance and mechanisms, we only conducted TME reprogramming experiments in a syngeneic colorectal murine tumor model in immunocompetent mice. The gene discussed is CDH17; the disease is neoplasm.